It achieves antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering the replication of bacterial DNA. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and has good antibacterial effect on most Enterobacteriaceae, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, but has poor effect on anaerobic bacteria and enterococci.

It achieves antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering the replication of bacterial DNA. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and has good antibacterial effect on most Enterobacteriaceae, Gram-negative bacteria, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, but has poor effect on anaerobic bacteria and enterococci.

It achieves antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering the replication of bacterial DNA. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and has good antibacterial effect on most Enterobacteriaceae, Gram-negative bacteria, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, but has poor effect on anaerobic bacteria and enterococci.

It achieves antibacterial effect by inhibiting the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hindering the replication of bacterial DNA. It has good antibacterial effect on most Enterobacteriaceae, some Gram-positive bacteria, Legionella, Mycoplasma, and Chlamydia, but has poor effect on anaerobic bacteria and enterococci.

Anti-myocardial ischemia, improve hemodynamics, improve blood rheology, protect the liver and reduce liver damage

Anti-myocardial ischemia, improve hemodynamics, improve blood rheology, protect the liver and reduce liver damage

1. Anti-myocardial ischemia: Intravenous injection of 0.8, 1.6, and 3.2 g/kg of this product can reduce the scope of myocardial infarction in dogs with acute myocardial ischemia caused by ligation of the left anterior descending coronary artery, slow down the acceleration of heart rate caused by ischemia, reduce the release of CK, LDH, and MDA in serum, and enhance SOD activity. 2. Effect on hemodynamics: Intravenous injection of 0.26, 0.78, and 2.34 g/kg of this product can significantly increase the coronary flow and cardiac output of anesthetized dogs, reduce femoral artery systolic pressure (SAP), diastolic pressure (DAP), and mean arterial pressure (MAP). 3. Improve blood rheology: Intravenous injection of 4 g/kg of this product can significantly reduce the whole blood viscosity, hematocrit, and platelet aggregation of rats with blood stasis syndrome caused by intravenous injection of glucose saline, and increase the maximum deformation coefficient of red blood cells. 4. Other effects Oral administration of 0.4 and 0.8 g/kg of this product can reduce experimental liver damage in mice caused by galactosamine, reduce the levels of plasma and liver homogenate peroxide (LPO) and malondialdehyde (MDA), and reduce the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

1. Anti-myocardial ischemia: Intravenous injection of 0.8, 1.6, and 3.2 g/kg of this product can reduce the scope of myocardial infarction in dogs with acute myocardial ischemia caused by ligation of the left anterior descending coronary artery, slow down the acceleration of heart rate caused by ischemia, reduce the release of CK, LDH, and MDA in serum, and enhance SOD activity. 2. Effect on hemodynamics: Intravenous injection of 0.26, 0.78, and 2.34 g/kg of this product can significantly increase the coronary flow and cardiac output of anesthetized dogs, reduce femoral artery systolic pressure (SAP), diastolic pressure (DAP), and mean arterial pressure (MAP). 3. Improve blood rheology: Intravenous injection of 4 g/kg of this product can significantly reduce the whole blood viscosity, hematocrit, and platelet aggregation of rats with blood stasis syndrome caused by intravenous injection of glucose saline, and increase the maximum deformation coefficient of red blood cells. 4. Other effects Oral administration of 0.4 and 0.8 g/kg of this product can reduce experimental liver damage in mice caused by galactosamine, reduce the levels of plasma and liver homogenate peroxide (LPO) and malondialdehyde (MDA), and reduce the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST).